Why controversial products claiming to help insomnia and migraines just got a big boost

The FDA advisory panel voted to recommend loosening regulations on six peptide treatments for insomnia and migraines, despite lacking rigorous clinical trial data. The decision marks a regulatory shift toward broader access to peptide products in a market that has grown rapidly through wellness channels.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.